Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions
Executive Summary
Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies
You may also be interested in...
Bristol Erbitux: Colorectal Refiling Within 9 Months; Broader Package In 2004
Bristol-Myers Squibb could refile Erbitux in irinotecan-refractory colorectal cancer by July, Exec VP Donald Hayden told the Bear Stearns healthcare conference in New York City Sept. 17
Bristol Erbitux: Colorectal Refiling Within 9 Months; Broader Package In 2004
Bristol-Myers Squibb could refile Erbitux in irinotecan-refractory colorectal cancer by July, Exec VP Donald Hayden told the Bear Stearns healthcare conference in New York City Sept. 17
Bristol Sales Force Turnover Rate Stabilizes; R&D Head Departing
Bristol-Myers Squibb's sales force turnover rate is stabilizing, Exec VP Don Hayden told a July 23 conference call